In fact, late last year we did exactly this by introducing some enhancements to Our Credo responsibilities that were inspired by feedback from more than 2,000 of our diverse Johnson & Johnson employees, representing all regions, segments and functions. The firm was the primary to standardize and mass produce first support kits, maternity kits, female merchandise and dental floss, all earlier than 1900. These are some of the many financial and strategic achievements that were made possible by the commitment of our more than 132,000 Johnson & Johnson colleagues, who passionately lead the way in improving the health and well-being of people around the world. aus oder wählen Sie 'Einstellungen verwalten', um weitere Informationen zu erhalten und eine Auswahl zu treffen. Johnson & Johnson’s total shareholder return for 2017 was more than 24%, exceeding our competitor composite, as well as exceeding most major indices, which, I am proud to say, Johnson & Johnson has done over the last three-, five-, 10- and 20-year periods. Our first priority is to fund our internal growth opportunities via R&D and SM&A (selling, marketing and administrative) initiatives. You are now leaving jnj.com. By just about every measure, Johnson & Johnson’s 133rd year was extraordinary. We have listened with great intent to the concerns voiced by many stakeholders over the pricing and transparency of products and our healthcare systems in the United States and around the world. Although Our Credo is literally etched in stone, it is a living document that, on a very few select occasions, we have evolved to keep pace with the world in which we live. This approach fosters diverse thinking, opinions and tactics, and expands value through our commitment to be the partner-of-choice for the most prestigious scientific laboratories, universities, technology companies and health systems around the world. This is how that individual spark of an idea becomes the next great collaborative breakthrough. We are structured to meet the current and future needs of patients and consumers globally, and to address the challenges and opportunities that the world of healthcare presents. This acquisition will accelerate our entry into digitally enabled robotics procedures with the potential for growth and expansion into other interventional applications. Throughout my seven years in this role, there have been many dramatic changes in global politics, the world economy, science, technology and culture. Delivering on the promises of our brands is both a personal and professional commitment. We also successfully launched critical products across each Medical Devices franchise throughout 2019, including: Our team continues to focus on improving our pipeline of innovation, while also responsibly managing our portfolio – which included the completion of the Advanced Sterilization Products divestiture and the execution of more than 50 acquisitions or strategic partnerships in 2019, that we expect will further augment our future growth. We’re very proud and excited that: With this industry-leading pipeline, commercial capabilities that create patient access, and robust R&D productivity, I’m confident that we are well positioned to continue delivering sustained, long-term, above-market growth in 2020 and beyond. For important information about these statements, including the risks, uncertainties and other factors that could cause actual results to vary materially from the assumptions, expectations and projections expressed in any forward-looking statements, the reader should review the enclosed Annual Report on Form 10-K for the fiscal year ended December 29, 2019, including in the sections captioned “Cautionary Note Regarding Forward Looking Statements” and “Item 1A. Use of this site constitutes your consent to application of such laws and regulations and to our Privacy Policy. We believe transparency is a fundamental responsibility of this Company. Another example is the ECHELON CIRCULAR Powered Stapler, a next generation technology to reduce complications in colorectal, gastric and thoracic cancer surgeries. Our U.S. Consumer business continued to grow above the market and our priority areas of Beauty and OTC delivered solid operational growth for the year. Additionally, I want to emphasize that product quality and safety are not only top business priorities for Johnson & Johnson, they are also core obligations embodied in Our Credo. Please click below to continue to that site. Our broad base is not just our heritage, it is a strategic choice, grounded and proven in long-term performance and our broad and deep understanding of the industry’s present and future. We also share the common objective of always making the health and well-being of the patients and consumers who use our products every day our number one priority, and it has been this way for the last 133 years. While Johnson & Johnson has modified over its lengthy historical past, the corporate continues to … Innovation is our calling card to the world of science and technology. An error occurred. Additionally, we signed 74 innovation deals as well as 29 new development deals, and we continue to make investments across all industries through Johnson & Johnson Innovation-JJDC, Inc. (JJDC). Our capital allocation strategy includes four key priorities: Given our financial strength, we can pursue all of these priorities simultaneously, as we did in 2018. We have a legacy of working hard to earn our customers’ trust and working equally hard to keep it—this commitment will always remain intact. The Investor Relations website contains information about Johnson & Johnson's business for stockholders, potential investors, and financial analysts. In 2018, Ebola made a resurgence in the Democratic Republic of the Congo (DRC). That is why we are committed to reducing the environmental footprint of our operations, products and supply chain by reaching our 2020 targets to reduce carbon emissions by 20% and procure 35% of electricity from renewable resources. Although we had been in business for almost 60 years, General Robert Wood Johnson II drafted Our Credo shortly before he took the Company public in 1944, creating an opportunity for people to invest in our vision of healthcare and to also understand how we would fulfill that vision. Johnson & Johnson made Fortune’s “Change the World List” again in 2018, in recognition of our efforts to help train surgeons, paramedics and other healthcare providers globally through our Johnson & Johnson Institute and other care programs. Johnson & Johnson (NYSE: JNJ) is among the many oldest and most prestigious American corporations which nonetheless exist at present. We blend heart, science and ingenuity to profoundly change the trajectory of health for humanity. Please see our Privacy Policy. We have established a sustainable business model that is built for the long-term and provides us with increased confidence about our strategic direction and the future of the healthcare industry. It is the middle class that drives global economic growth and with it, the demand for greater access to quality healthcare. And because we are committed to thriving in this change environment, our goal is not merely to adapt to change, but to be the catalyst for needed change. EEO Is the Law | EEO Is the Law GINA Supplement | Do Not Sell My Personal Information. The CARTO VIZIGO steerable sheath in our market-leading electrophysiology business. Explicitly put the patient first and at the center of our focus; Reflect the needs of a changing world and a new generation of employees; Underscore our commitment to diversity and inclusion; and. Podatki o napravi in internetni povezavi, vključno z naslovom IP, Dejavnosti brskanja in iskanja med uporabo spletnih mest in aplikacij družbe Verizon Media. I believe that no company on Earth is better positioned than Johnson & Johnson to capture this opportunity and lead the healthcare industry. Our Credo remains as relevant today as when it was first introduced 75 years ago, and I’m confident that it will propel Johnson & Johnson forward for the next 75 years and beyond. 2019 Health for Humanity Report. In 2019, we plan to launch 20 to 25 major products, including ACUVUE OASYS with Transitions™ Light Intelligent Technology™, a first-of-its-kind contact lens that was named one of TIME Magazine’s Best Inventions of 2018. At the same time, we fully recognize that our progress has not been uniform across the Medical Devices portfolio. As I look at today’s health care landscape, it’s incredibly clear that the pace of change has never been greater, or frankly, more exciting. Alex GorskyChairman and Chief Executive OfficerJohnson & Johnson. This is illustrated by: The Strategic Advantage of Our Broad Base Positioned across three vital aspects of healthcare—Pharmaceutical, Consumer and Medical Devices—we have unique insight into challenges and opportunities whenever and wherever they emerge. The world has been the campus for my education in human health, as it has been for my Johnson & Johnson colleagues. Required fields are marked *, The Top 5 Johnson & Johnson Shareholders (JNJ). Questions? Contact Lens, which delivered growth at or above the market for the fourth straight year, Energy and Endocutters businesses growing mid-single digits, and. Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. We are confident in our ability to lead with certainty and to responsibly navigate our way through these potential challenges. It is also a great example of how we are leveraging innovation across our business segments, as our 3D printing capability originated within Medical Devices. Please see our Privacy Policy. Every investor in Johnson & Johnson should be aware of the most powerful shareholder groups.Institutions often own shares in more established companies, while it's not unusual to … Prior to becoming a member of Johnson & Johnson, Peterson served as chairman & CEO of Bayer CropScience AG in Germany. We know that innovation drives our Pharmaceutical business’s success, and we are very excited about the U.S. Food and Drug Administration (FDA) approval of SPRAVATO™ (esketamine) CIII Nasal Spray for adults with Treatment Resistant Depression (TRD), who have cycled through multiple treatments without relief. As of February 25, 2020, Gorsky holds 2.9 million shares. Your use of the information on this site is subject to the terms of our Legal Notice. Shareholder Tools. We deployed approximately $7 billion to complete transactions that fortify our commitment to digital surgery for a more personalized and elevated standard of healthcare, and that enhance our position in consumer skin health. We clearly recognize the important role we play in leading responsibly and representing our industry with integrity. You are now leaving jnj.com. Pharmaceutical Companies of Johnson & Johnson, Advancing New Healthcare Solutions Through Collaboration, Reimagining the Way Healthcare Is Delivered, Learn About the Company's Rich Heritage at Our Digital Museum. Consumer In 2018, fueled by our iconic brands and deep consumer insights, our Consumer business achieved above-market growth. Dies geschieht in Ihren Datenschutzeinstellungen. As I just mentioned, we continue to innovate in surgery. However, across Johnson & Johnson, we have always operated under the belief that there is a tightly linked connection between our Company’s purpose—to advance health for humanity, and our performance—to create and deliver shareholder value. This is how we live into Our Credo values and apply equal focus and commitment to both our performance and purpose. It’s also another strong demonstration that our purpose, focused on helping patients, is driving our business—just as it should be. Email Alerts Subscription. globaltel: Glad I read this article.